Incyte

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Incyte Corporation
TypePublic
NasdaqINCY
NASDAQ-100 Component
S&P 500 Component
Industrypharmaceutical company
Founded2002 (2002)
Headquarters
Key people
Hervé Hoppenot (Chairman, President, and CEO, 2014)
RevenueIncrease $US 2.67 billion (2020)
Decrease $US (296) million (2020)[1][2]
Total assetsIncrease $US 3.56 billion (2020)
Total equityIncrease $US 2.611 billion (2020)
Number of employees
1600+[3] (2020)
Websitewww.incyte.com
Footnotes / references
[4]

Incyte Corp is an American multinational pharmaceutical company with headquartes in Wilmington, Delaware[5] and Morges, Switzerland.[6] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991[7] and Incyte Genomics, Inc. of Delaware.[8] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[9]

Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History[edit]

In 2014, Incyte named Hervé Hoppenot president and CEO, and in 2015 he was appointed chairman of the Board of Directors.[10][11] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[11]

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[12]

In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[13] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[14]

Pharmaceuticals[edit]

Incyte Corporation currently has four marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) and Iclusig (ponatinib).[15]

In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[16]

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[17][18] It gained EU approval in February 2017.[19] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[20][21] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[22][23]

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[24][25]

References[edit]

  1. ^ https://www.nasdaq.com/market-activity/stocks/incy/financials
  2. ^ https://www.macrotrends.net/stocks/charts/INCY/incyte/net-income
  3. ^ "Incyte". Fortune 500. Fortune Media IP Limited. 18 May 2020. Company information. Retrieved 19 December 2020.
  4. ^ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, archived from the original on January 26, 2013, retrieved May 6, 2012
  5. ^ "INCY". www.nasdaq.com. Retrieved 2021-07-26.
  6. ^ "Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte’s drug development operations, and provides efficient access to key clinical trial experts and institutions.
  7. ^ Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
  8. ^ "Certificate of Ownership and Merger". www.sec.gov. Retrieved 2021-07-26.
  9. ^ "Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
  10. ^ "Leadership | Incyte". www.incyte.com. Retrieved 2021-07-26.
  11. ^ a b "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
  12. ^ "Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.
  13. ^ "MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab".
  14. ^ "MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab".
  15. ^ "incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.
  16. ^ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
  17. ^ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Archived from the original on 8 March 2015. Retrieved 2 Mar 2015.
  18. ^ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
  19. ^ "Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.
  20. ^ Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.
  21. ^ Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.
  22. ^ Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA.
  23. ^ "Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.
  24. ^ Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer (Oxford, England : 1990). 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.
  25. ^ Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.

External links[edit]